GGrantIndex
← Leaderboards

Julian A Simon

Fred Hutchinson Cancer Research Center

Google Scholar ↗PubMed ↗ORCID ↗
$13,150,957
Attributed
$15,120,025
Total exposure
16
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$37,504,262 · 18

By mechanism

U54$27,656,425 · 8
R01$7,963,046 · 6
N01$953,000 · 1
U01$516,453 · 1
R21$415,338 · 1
U56$0 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Programs”

Research focus

ProgramsMalignant NeoplasmsFutureCommunitiesMemberCancer Health DisparityScientistFundingSuccessInstitutionBaseEvaluationCollaborationsParticipantResearch Project GrantsStudentsResearch PersonnelTrainingOutreachUniversitiesAnticancer ResearchEducation ResearchResourcesFaculty

Grant awards (78)

2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,422,885
U54 · FY2025 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,178,138
U54 · FY2025 · CA
Administrative Core$162,297
U54 · FY2025 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$156,861
U54 · FY2025 · CA · contact PI
Planning & Evaluation Core$98,106
U54 · FY2025 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,255,011
U54 · FY2024 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,123,008
U54 · FY2024 · CA
Administrative Core$134,491
U54 · FY2024 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$114,443
U54 · FY2024 · CA · contact PI
Planning & Evaluation Core$75,639
U54 · FY2024 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,410,939
U54 · FY2023 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,182,113
U54 · FY2023 · CA
Administrative Core$184,457
U54 · FY2023 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$165,706
U54 · FY2023 · CA · contact PI
Planning & Evaluation Core$104,158
U54 · FY2023 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,354,604
U54 · FY2022 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,146,893
U54 · FY2022 · CA
Planning and Evaluation Core$598,720
U54 · FY2022 · CA · contact PI
Administrative Core$273,979
U54 · FY2022 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$164,148
U54 · FY2022 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,170,300
U54 · FY2021 · CA
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$782,992
U54 · FY2021 · CA · contact PI
Planning and Evaluation Core$594,005
U54 · FY2021 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$458,198
U54 · FY2021 · CA · contact PI
Planning and Evaluation Core$346,183
U54 · FY2021 · CA · contact PI
Administrative Core$226,763
U54 · FY2021 · CA · contact PI
Administrative Core$158,417
U54 · FY2021 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$123,270
U54 · FY2021 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$94,912
U54 · FY2021 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,407,739
U54 · FY2020 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,154,810
U54 · FY2020 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$467,882
R01 · FY2020 · CA · contact PI
Administrative Core$267,611
U54 · FY2020 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$172,874
U54 · FY2020 · CA · contact PI
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$106,872
R01 · FY2020 · CA · contact PI
Planning and Evaluation Core$86,140
U54 · FY2020 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,308,679
U54 · FY2019 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,120,967
U54 · FY2019 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$557,510
R01 · FY2019 · CA · contact PI
Administrative Core$240,440
U54 · FY2019 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$137,471
U54 · FY2019 · CA · contact PI
Planning and Evaluation Core$88,454
U54 · FY2019 · CA · contact PI
2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,439,317
U54 · FY2018 · CA · contact PI
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch$1,161,316
U54 · FY2018 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$574,754
R01 · FY2018 · CA · contact PI
Administrative Core$259,924
U54 · FY2018 · CA · contact PI
Research Education About Cancer and Health (REACH) Core$183,922
U54 · FY2018 · CA · contact PI
Planning and Evaluation Core$58,797
U54 · FY2018 · CA · contact PI
Partnership for the Advancement of Cancer Research: NMSU-FHCRC (2 of 2)$1,153,222
U54 · FY2017 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$574,754
R01 · FY2017 · CA · contact PI
Partnership for the Advancement of Cancer Research: NMSU-FHCRC (2 of 2)$1,153,106
U54 · FY2016 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$573,293
R01 · FY2016 · CA · contact PI
Drug Discovery for the Prevention of Hearing Loss$69,213
R01 · FY2015 · DC
Drug Discovery for the Prevention of Hearing Loss$70,430
R01 · FY2014 · DC
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$430,192
R01 · FY2013 · DC · contact PI
Drug Discovery for the Prevention of Hearing Loss$156,207
R01 · FY2013 · DC
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$33,387
R01 · FY2013 · DC · contact PI
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$346,194
R01 · FY2012 · DC · contact PI
Drug Discovery for the Prevention of Hearing Loss$200,522
U01 · FY2012 · NS
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$95,408
R01 · FY2012 · DC · contact PI
Drug Discovery for the Prevention of Hearing Loss$73,330
U01 · FY2012 · NS
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$346,298
R01 · FY2011 · DC · contact PI
Drug Discovery for the Prevention of Hearing Loss$242,601
U01 · FY2011 · NS
Inhibition of B-Catenin Signaling for Treatment of Hepatocellular Carcinoma$185,658
R21 · FY2011 · CA · contact PI
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$357,854
R01 · FY2010 · DC · contact PI
Inhibition of B-Catenin Signaling for Treatment of Hepatocellular Carcinoma$229,680
R21 · FY2010 · CA · contact PI
Chemoprotection Against Aminoglycoside-Induced Ototoxicity$377,733
R01 · FY2009 · DC · contact PI
New mitosis specific anticancer agents$358,975
R01 · FY2005 · CA
New mitosis specific anticancer agents$358,975
R01 · FY2004 · CA
New mitosis specific anticancer agents$358,975
R01 · FY2003 · CA
New mitosis specific anticancer agents$358,975
R01 · FY2002 · CA
STRATEGIES FOR CONTEXT SPECIFIC ANTICANCER THERAPIES$256,568
R01 · FY2002 · CA
Anticancer activity of native plants of the Southwest$0
U56 · FY2002 · CA
New mitosis specific anticancer agents$358,975
R01 · FY2001 · CA
NOVEL DOUBLE STRAND BREAK PRODUCING COMPOUNDS$264,880
R01 · FY2001 · CA
STRATEGIES FOR CONTEXT SPECIFIC ANTICANCER THERAPIES$249,098
R01 · FY2001 · CA
LABORATORY SUPPORT FOR GOVERNMENT SCIENTISTS$953,000
N01 · FY2000 · CM
STRATEGIES FOR CONTEXT SPECIFIC ANTICANCER THERAPIES$259,644
R01 · FY2000 · CA